Ticker LaunchReverse merger · Completed · VYNT
StemoniX, Inc.
Reverse merger with Cancer Genetics, Inc. (CGIX)
StemoniX, Inc. merged into Cancer Genetics, Inc. (CGIX), a drug discovery and preclinical oncology services provider, in a reverse merger that takes the private company public. The deal was announced on Aug 24, 2020 and closed on Mar 30, 2021. The combined company trades as Vyant Bio, Inc. (VYNT) on Nasdaq.
Vyant Bio, Inc. develops StemoniX's microOrgans platform and AnalytiX augmented intelligence tools for drug discovery, alongside the historical Cancer Genetics biotech business.
- Status
- Completed
- Private company
- StemoniX, Inc.
- Public company
- Cancer Genetics, Inc. (CGIX)
- Public company business before
- drug discovery and preclinical oncology services provider
- Announced
- Aug 24, 2020
- Closed
- Mar 30, 2021
- Combined company
- Vyant Bio, Inc. (VYNT)
- Exchange
- Nasdaq
- Sector
- Biotech & pharma
More on this deal for subscribers
- Ownership split between private and public holders
- Analyst notes from the filings
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Closing 8-K Apr 5, 2021
- Announcement press release
- All filings on EDGAR CIK 1349929
Other completed reverse mergers
- MyMD Pharmaceuticals (Florida), Inc.into Akers Biosciences, Inc. · Apr 16, 2021
- 374Water Inc.into PowerVerde, Inc. · Apr 16, 2021
- Brooklyn ImmunoTherapeutics LLCinto NTN Buzztime, Inc. · Mar 25, 2021
- Chemomab Ltd.into Anchiano Therapeutics Ltd. · Mar 16, 2021
- Envirotech Drive Systems, Inc.into ADOMANI, Inc. · Mar 16, 2021
- Cosmos Capital Limitedinto Wize Pharma, Inc. · Mar 9, 2021